Stewart Jeffrey Ryan — SEC insider filings
SEC reporting owner CIK 1761675. 21 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2020-12-11 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 9 filings — 301,918 shares, $54,935,204 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 54.
- Largest priced transaction: sale of 40,619 shares @ $293.60 ($11,925,738) in AbbVie Inc., filed 2026-11-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | EVP, CHIEF COMMERCIAL OFFICER | 21 | — | 15 legs · 301,918 sh · $54,935,204 | 54 |
Insider filings — Stewart Jeffrey Ryan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 16,070 @ $114.36 · Option exercise (M): 24,549 @ $93.50 · Sale (S): 40,619 @ $293.60 · Gift (G): 3,450 @ $0 · Option exercise (M): 16,070 (derivative) @ $0 · Option exercise (M): 24,549 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 23,812 @ $232.08 | EDGAR |
| 2026-02-20 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 26,063 @ $0 · Grant/award (A): 9,266 @ $0 · Grant/award (A): 9,432 @ $0 · Grant/award (A): 8,988 @ $0 · Grant/award (A): 26,812 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 25,700 @ $79.02 · Sale (S): 25,700 @ $209.49 · Sale (S): 33,132 @ $210.54 · Option exercise (M): 25,700 (derivative) @ $79.02 | EDGAR |
| 2025-03-04 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 20,226 @ $205.02 | EDGAR |
| 2025-02-18 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 19,111 @ $0 · Grant/award (A): 7,840 @ $0 · Grant/award (A): 9,268 @ $0 · Grant/award (A): 9,432 @ $0 · Grant/award (A): 33,854 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 26,110 @ $61.36 · Sale (S): 26,110 @ $178.85 · Sale (S): 5,099 @ $179.03 · Sale (S): 27,740 @ $178.69 · Option exercise (M): 26,110 (derivative) @ $61.36 | EDGAR |
| 2024-03-01 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 26,121 @ $178.99 | EDGAR |
| 2024-02-20 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 33,042 @ $0 · Grant/award (A): 8,810 @ $0 · Grant/award (A): 7,840 @ $0 · Grant/award (A): 9,268 @ $0 · Grant/award (A): 39,085 (derivative) @ $0 | EDGAR |
| 2023-03-15 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 21,810 @ $54.86 · Sale (S): 21,810 @ $152.30 · Sale (S): 31,315 @ $152.27 · Option exercise (M): 21,810 (derivative) @ $54.86 | EDGAR |
| 2023-03-02 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 24,910 @ $154.28 | EDGAR |
| 2023-02-21 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 32,085 @ $0 · Grant/award (A): 7,486 @ $0 · Grant/award (A): 8,812 @ $0 · Grant/award (A): 7,842 @ $0 · Grant/award (A): 35,111 (derivative) @ $0 | EDGAR |
| 2022-03-25 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 27,690 @ $58.88 · Sale (S): 27,690 @ $159.20 · Option exercise (M): 27,690 (derivative) @ $58.88 | EDGAR |
| 2022-03-01 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 17,093 @ $149.54 · Sale (S): 6,229 @ $147.43 · Sale (S): 12,659 @ $148.49 · Sale (S): 2,600 @ $149.04 | EDGAR |
| 2022-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 19,209 @ $0 · Grant/award (A): 4,176 @ $0 · Grant/award (A): 7,486 @ $0 · Grant/award (A): 7,710 @ $0 · Grant/award (A): 13,837 @ $0 · Grant/award (A): 37,215 (derivative) @ $0 | EDGAR |
| 2021-12-17 | 4 | AbbVie Inc. (ABBV) | Sale (S): 2,152 @ $128 | EDGAR |
| 2021-12-14 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 1,713 @ $124.15 | EDGAR |
| 2021-03-02 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 10,957 @ $107.74 · Sale (S): 13,773 @ $108.59 | EDGAR |
| 2021-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 10,098 @ $0 · Grant/award (A): 2,970 @ $0 · Grant/award (A): 4,176 @ $0 · Grant/award (A): 7,486 @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2020-12-31 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 25,290 @ $51.42 · Sale (S): 25,290 @ $105 · Option exercise (M): 25,290 (derivative) @ $0 | EDGAR |
| 2020-12-11 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 1,791 @ $108.67 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1761675 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs